Stocks · News reference
Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On October 13, 2026, Xeris Biopharma Holdings, Inc. (the "Company"), through its wholly owned subsidiary, Xeris Pharmaceuticals, Inc., filed patent infringement lawsuits in the United States District Court for
Filed: 2026-10-14 AccNo: 0001867096-26-000091 Size: 170 KB Item 8.01: Other Events
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.
Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive